“…Of note is that indomethacin, a NSAID used in rheumatic diseases for alleviating pain and inflammation [292], has been recently shown to behave like an electrophilic molecule that targets the Cys151 residue of KEAP1, inducing NRF2 activation and increased expression of some canonical NRF2 target genes (Nag-1/GDF15, CAT, GAR, GCLM, HMOX1, NQO1 and TALDO1) in primary human and mouse macrophages, independent of cyclooxygenase inhibition [268]. This study also demonstrated NRF2 target engagement by indomethacin in mice with endotoxemia and gout, but no human study has been so far performed to bring again into focus indomethacin for controlling pain, inflammation and redox disturbances in RA.…”